SAN DIEGO, CA and VANCOUVER, BC, Nov. 6, 2012 /PRNewswire/ - Sophiris Bio Inc.
(TSX: SHS), a urology company developing a late-stage, highly targeted
treatment for benign prostatic hyperplasia (BPH or enlarged prostate),
today announced that Randall E. Woods, President and Chief Executive
Officer, will present an overview of the Company at the Lazard Capital
Markets 9th Annual Healthcare Conference in New York. Mr. Woods' presentation will
take place at 4:00 p.m. EST on Tuesday, November 13, 2012.
A live webcast of the presentation may be accessed via the Sophiris
website at www.sophirisbio.com. A replay of the presentation will be available on the Company's
website for 90 days.
About Sophiris Bio:
Sophiris Bio Inc. is a urology company developing a late-stage, highly
targeted treatment for benign prostatic hyperplasia (BPH or enlarged
prostate), an unsatisfied market with large potential demand. PRX302,
the company's lead candidate for BPH, is designed to be as efficacious
as pharmaceuticals, less invasive than the surgical interventions, and
without the sexual side effects seen with existing treatments. Sophiris
is advised by world-leading urologists, backed by experienced
investors, and led by a team that has achieved more than twenty drug
approvals including several drugs with annual sales in excess of $1
billion. For more information, please visit www.sophirisbio.com.
Certain statements included in this press release may be considered
forward-looking, including statements about the potential for PRX302.
Such statements involve known and unknown risks, uncertainties and
other factors that may cause actual results, performance or
achievements to be materially different from those implied by such
statements, and therefore these statements should not be read as
guarantees of future performance or results. All forward-looking
statements are based on Sophiris Bio's' current beliefs as well as
assumptions made by and information currently available to Sophiris Bio
and relate to, among other things, anticipated financial performance,
business prospects, strategies, regulatory developments, market
acceptance and future commitments. Readers are cautioned not to place
undue reliance on these forward-looking statements, which speak only as
of the date of this press release. Due to risks and uncertainties,
including the risks and uncertainties inherent in late stage drug
development and risks relating to obtaining FDA and other regulatory
approvals as well as risks identified by Sophiris Bio in its public
securities filings; actual events may differ materially from current
expectations. Sophiris Bio disclaims any intention or obligation to
update or revise any forward-looking statements, whether as a result of
new information, future events or otherwise.
SOURCE Sophiris Bio, Inc.